-
International Journal of Nanomedicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Water-soluble fullerene (C60) inhibits the osteoclast differentiation and bone destruction in arthritis
Original Research
(3102) Views (787) Full article downloads
Authors: Kazuo Yudoh, Rie Karasawa, Kayo Masuko, et al
Published Date October 2009
Volume 2009:4 Pages 233 - 239
DOI: http://dx.doi.org/10.2147/IJN.S7505
Kazuo Yudoh1, Rie Karasawa1, Kayo Masuko2, Tomohiro Kato2
1Department of Frontier Medicine, 2Department of Biochemistry, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan
Abstract: Recently, it has been demonstrated that oxygen free radicals have an important role as a signaling messenger in the receptor activator NFκB (RANK) signal pathway required for osteoclast differentiation. The aim of this study was to examine the potential of a strong free-radical scavenger, water-soluble fullerene (C60), as a protective agent against the RANK-induced osteoclastogenesis and osteoclastic bone destruction in arthritis, both in vitro and in vivo. The effects of C60 on the RANK-induced osteoclastogenesis and osteoclastic bone resorption were examined in vitro. Adjuvant-induced arthritic rats were used as an animal model of arthritis. Rats were divided into two subgroups: control and treatment with C60 at 1.0 µM. The left ankle joint was injected intra-articularly with water-soluble C60 (20 µl) in the C60-treated group, while, as a control, the left ankle joint in the control rats received phosphate-buffered saline (20 µl) once weekly for eight weeks. Ankle joint tissues were prepared for histologic analysis. C60 significantly inhibited the responses of osteoclast precursor cells to RANK ligand, including osteoclast differentiation and osteoclastic bone resorption in vitro. In adjuvant-induced arthritic rats, intra-articular treatment with C60 in vivo reduced the number of osteoclasts and alleviated bone resorption and destruction in the joints, while control ankle joints showed progression of joint destruction with time. These findings indicate that C60 downregulates the RANK-induced osteoclast differentiation and is a potential therapeutic agent for inhibition of osteoclastic bone destruction in arthritis.
Keywords: fullerene, osteoclast, bone resorption arthritis, antioxidant
Other articles by Dr Kazuo Yudoh
Readers of this article also read:
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Binding fullerenol C60(OH)24 to dsDNA
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
Water-soluble fullerene (c60) inhibits the development of arthritis in the rat model of arthritis
Biomedical applications of functionalized fullerene-based nanomaterials
Amino acid management of Parkinson’s disease: a case study
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Interested in being a peer-reviewer?
Click here to register.
- Display new articles on your site
Use our widget to show articles on your own site
- Applications of gold nanoparticles in cancer nanotechnology
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
- Gold nanoparticles: From nanomedicine to nanosensing
- Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases




